EORTC protocol 58921

Randomized phase III study comparing IDA versus MTZ in induction and intensification treatment of AML or MDS in children
Trial StatusFurther follow-up after final analysis of primary endpoint
DatesDate of activation: 05-Mar-93
Closed on : 16-Dec-02
Data management at EORTCFull
Phase3
Randomized trialYes
TypeAdvanced
Targeted Sample size310
Number of steps1
Drug
Study StaffCatherine Behar (Study Coordinator) - CHU de Reims - American Memorial Hospital , Reims
Yves Bertrand (Study Coordinator) - CHU de Lyon - Institut d'Hematologie et d'Oncologie Pediatrique, Lyon
Gaetan de Schaetzen (Project Manager) - EORTC Headquarters, Brussels, gaetan.deschaetzen( at )eortc.be, +32 27741618
Type of cancerAcute Myelogenous Leukemia
Participating GroupsEORTC Children's Leukemia Group(Coordinating Group)
Protocol summaryCancer.gov (PDQ)
ClinicalTrials.gov
NCT numberNCT00002517
EudraCT
Back to Protocol section